In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stryker Enters China Race With Trauson Bid

Executive Summary

The race to acquire a local foothold in China’s medical device industry is on. Stryker's bid to pay $764 million for Trauson Holdings would take out China’s second sizable domestic supplier of orthopedic implants.

You may also be interested in...



ArthroCare Bid Signals Ortho Consolidation

If completed, Smith & Nephew’s acquisition of ArthroCare would help it diversify into the ENT market, but the deal may not get done as analysts speculate that competitors Stryker and J&J could step in with counteroffers. The interest surrounding ArthroCare emphasizes the pressures being put on large joint makers to find new ways of making money in orthopedics.

ArthroCare Bid Signals Ortho Consolidation

If completed, Smith & Nephew’s acquisition of ArthroCare would help it diversify into the ENT market, but the deal may not get done as analysts speculate that competitors Stryker and J&J could step in with counteroffers. But the interest surrounding Austin, TX-based ArthroCare emphasizes the pressures being put on large joint makers to find new ways of making money in orthopedics.

Stryker Aims To Be Greater Than The Sum Of Its Parts

Stryker says it is shifting from “fierce decentralization” to more collaboration between business units to offer customers more holistic solutions.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV003945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel